Form 4: Charles River Laboratories Executive Reports Significant RSU Grant and Tax-Related Share Disposition

A Charles River Laboratories executive, Shannon M. Parisotto, reported the acquisition of 5,603 restricted stock units and a subsequent disposition of 105 shares for tax withholding purposes.

Summary

• Shannon M. Parisotto, CEVP, Discovery & Safety Assessment at Charles River Laboratories International, Inc. (CRL), reported transactions involving company common stock.
• On May 30, 2025, Parisotto acquired 5,603 shares of common stock, identified as unvested restricted stock units, at a price of $135.63 per share.
• These restricted stock units are scheduled to vest annually on May 30, 2026, May 30, 2027, May 30, 2028, and May 30, 2029.
• On May 31, 2025, Parisotto disposed of 105 shares of common stock at $135.63 per share. This disposition is typically for tax withholding purposes related to the vesting of equity awards.
• Following these transactions, Parisotto directly beneficially owns 12,997 shares and indirectly owns 28,510 shares through Karpathos Investments LLC, totaling 41,507 shares.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it indicates an executive receiving a significant equity award, aligning their interests with the company's long-term performance. The disposition is for tax purposes, which is a routine and expected event, not a negative signal.

Positives

• The acquisition of 5,603 restricted stock units indicates continued equity compensation for a key executive, aligning management's interests with shareholder value.
• The vesting schedule over multiple years (until 2029) suggests a long-term commitment of the executive to the company's performance.

Negatives

• The disposition of 105 shares, while common for tax withholding, represents a minor reduction in direct beneficial ownership.

Future Outlook

The document indicates a long-term equity incentive structure for a key executive, with restricted stock units vesting annually through May 2029, suggesting an expectation of continued executive tenure and performance alignment.

Industry Context

This Form 4 filing reflects standard executive compensation practices within the life sciences and pharmaceutical services industry, where equity awards like Restricted Stock Units (RSUs) are commonly used to incentivize and retain key management personnel, aligning their financial interests with long-term company performance.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) with a multi-year vesting schedule is a common and widely accepted practice for executive compensation across various industries, including the life sciences sector.
• Companies like LabCorp (LH), IQVIA (IQV), and Catalent (CTLT) also frequently utilize similar equity-based incentives to retain talent and align executive interests with shareholder value.
• The specific grant size and vesting terms are generally benchmarked against peer group compensation data to ensure competitiveness and effectiveness in attracting and retaining top-tier executives.

Related Party Transactions

• Shannon M. Parisotto indirectly owns 28,510 shares through Karpathos Investments LLC.

Stakeholder Impact

• Shareholders: The grant of RSUs to a key executive aligns management's long-term interests with shareholder value creation.
• Employees: Reflects the company's compensation strategy, potentially influencing employee morale and retention through equity incentives.

Next Steps

• Annual vesting of the acquired restricted stock units on May 30, 2026, May 30, 2027, May 30, 2028, and May 30, 2029.

Key Dates

Recommendation

Keywords

Charles River Laboratories, CRL, SEC Form 4, Insider Trading, Restricted Stock Units, RSU, Equity Compensation, Shannon M. Parisotto, Executive Compensation, Stock Ownership